

---

## Prescribing Non-Opioid Drugs in End-Stage Kidney Disease

Andrew Wilcock, DM, FRCP,  
Sarah Charlesworth, BPharm, PG Dip Clin Pharm, MRPharmS,  
Robert Twycross, DM, FRCP,  
Anne Waddington, BPharm, PG Dip Clin Pharm,  
Olivia Worthington, MRCP, FFICM,  
Fliss E.M. Murtagh, PhD, FRCP, MRCGP, Jenny Beavis, PDACN, MPET, NP,  
Samuel King, MRCP,  
Mary Mihalyo, BS, PharmD, RPh, CGP, BCPS, CDE, and  
Aleksandra Kotlinska-Lemieszek, MD, PhD

University of Nottingham (A.W.), Nottingham, United Kingdom; Nottingham University Hospitals (S.C.), Nottingham, United Kingdom;

Oxford University (R.T.), Oxford, United Kingdom;

Aintree University Hospital NHS Foundation Trust (A.W.), Liverpool, United Kingdom;

Aintree University Hospital NHS Foundation Trust (O.W.), Liverpool, United Kingdom;

College London (F.E.M.M.), Cicely Saunders Institute, London, United Kingdom;

Royal Melbourne Hospital (J.B.), Parkville, Australia;

Elizabeth Hospice (S.K.), Ipswich, United Kingdom;

Mylan School of Pharmacy, Duquesne University (M.M.), Pittsburgh, Pennsylvania, USA;

Karol Marcinkowski University of Medical Sciences and Hospice Palium, University Hospital of the Lord's Transfiguration (A.K.-L.), Poznan, Poland

---

### Introduction

Palliative care services are increasingly involved in the care of patients with chronic kidney disease, either alone or as a comorbid condition. Because renal impairment often changes the pharmacokinetic and/or pharmacodynamic effects of a drug, this presents a challenge for prescribers.

This article provides guidance for prescribing non-opioid drugs commonly used for palliative care symptom relief in patients with end-stage kidney disease (ESKD; i.e. Chronic Kidney Disease Stage 5, eGFR <15mL/ min/1.73m<sup>2</sup>) whether or not they are receiving dialysis. Opioids are not included, nor symptom relief in the last hours—days of life, because specific guidance is available elsewhere.<sup>1–4</sup>

Tables have been produced to highlight, when possible, the most, intermediate and least 'renally safe' drugs for chronic use. However, sometimes the cautious use of a familiar drug may be preferable to an unfamiliar (albeit 'renally safer') one. Similarly, we do not advocate the automatic switching of patients to a 'renally safer' drug when an alternative is proving satisfactory. Finally, this article aims to complement and not replace specialist renal unit guidance.

### Safe prescribing in ESKD

Pharmacologically, the most important consequence of ESKD is increased toxicity as a result of accumulation of a renally excreted drug ± active metabolites. ESKD also has many other consequences which may alter the effect of a drug, whether or not accumulation occurs, e.g. an enhanced sedative effect of a centrally-acting drug (Box A).

### Box A. Drug-related consequences of ESKD<sup>5</sup>

#### Pharmacokinetic Absorption

↓ gastric pH, ↓ gut wall oedema → ↓ PO absorption

#### Distribution

↓ oedema/ascites → ↓ volume of distribution → ↓ effect of water soluble drugs

↓ cachexia or dehydration → ↓ volume of distribution → ↓ effect of water soluble drugs

↓ drug removal transporters in the blood-brain barrier, e.g. p-glycoprotein → ↓ CNS effects

↓ albumin levels and binding capacity → ↓ unbound (active) fraction of highly protein-bound drugs → ↓ effect (and metabolism)

↓ tissue binding → ↓ volume of distribution → ↓ effect

#### Metabolism

↓ hepatic enzyme function, particularly CYP450 → ↓ metabolism → variable effect depending on drug, e.g. pro-drug, active metabolite

#### Elimination

↓ GFR and ↓ tubular secretion → ↓ elimination of parent drug/active metabolite → ↓ effect, ↓ risk of toxicity

↓ drug removal transporters, e.g. p-glycoprotein → ↓ biliary and GIT elimination → ↓ elimination of parent drug/active metabolite → ↓ effect, ↓ risk of toxicity

#### Pharmacodynamic

Uraemia can alter the clinical response to certain drugs:

↓ sensitivity to drugs acting on the CNS

↓ risk of hyperkalaemia with potassium-sparing-drugs

↓ risk of GI bleeding or oedema with NSAIDs

↓ efficacy or ↓ toxicity of drugs such as warfarin or statins (due to altered physiological or pathological processes involved in other conditions)

Electrolyte imbalance can increase the risk of cardiac arrhythmia with QT prolonging drugs

### Aims and development of the tables

The tables and accompanying text were developed for the Palliative Care Formulary (see [www.palliativedrugs.com](http://www.palliativedrugs.com)) to provide user-friendly summaries to guide rational and safe prescribing in patients with ESKD (± dialysis), by raising awareness of:

- suitable drugs and their starting doses
- suitable alternatives when patients experience undesirable effects
- the potential risks of using a less renally safe drug.

The tables cover the most common symptom relief drug classes. Because it is generally good practice to become experienced in using relatively few drugs well, the list is purposely limited.

Although ESKD is defined as an eGFR <15mL/min/1.73m<sup>2</sup>, most sources of prescribing information use creatinine clearance to guide drug dosing, with slight variation in the values reflecting ESKD. Thus, for the prescribing recommendations in Tables 1-6, a creatinine clearance of <10mL/min has been adopted.

Initially, for each drug within each class, a full data table was produced summarizing the key pharmacokinetic data available from several established sources (Box B); see supplementary Appendix 1 online. In turn, the full data were used to inform Tables 1-6. Drugs were categorized as 'generally safe', 'use cautiously' and 'avoid if possible' from a purely renal perspective, according to their risk of accumulation with chronic use in ESKD.

The pharmacokinetic information derived from the established sources sometimes varied and was occasionally contradictory. Generally, information within Tables 1-6 reflects either the best evidenced and/or the majority view of the established sources. Where there was a lack of data, information was sought from the wider literature (Box B).

In the established sources, because specific prescribing advice was also noted to vary, additional sources of information were consulted (Box B). The prescribing advice was summarised separately (see supplementary Appendix 2 online) and circulated among the contributing authors to achieve a consensus view which is reflected in Tables 1-6. It is important to note that the consensus view may include off-label use. However, it is impractical to highlight all cases of off-label use because this can vary according to country, brand, indication, formulation, dose, route of administration or patient population. Prescribers should

---

## Box B. Sources of information used

Established sources  
American Hospital Formulary Service Drug Information<sup>7</sup>  
Martindale: The Complete Drug Reference<sup>8</sup>  
Oxford Specialist Handbook: Kidney disease from advanced disease to bereavement<sup>9</sup>  
Package Inserts (USA)  
Renal Drug Database<sup>10</sup>  
Summary of Product Characteristics (UK)

Additional sources  
Antidepressants<sup>11-16</sup>  
Anti-emetics<sup>17,18</sup>  
Anti-epileptics<sup>19-23</sup>  
Benzodiazepines<sup>24-26</sup>  
Miscellaneous drugs<sup>27,28</sup>  
Prescribing advice<sup>1,12,29-33</sup>

### Use of the tables

The tables should be used in conjunction with the accompanying text which highlights any general considerations for that class of drug and provides a commentary to help inform choice. As far as possible, specific prescribing advice is given. Even when a drug appears to be 'renally safe', because of the other effects of renal impairment (Box A), smaller starting doses and a slower titration than usual is generally advisable, particularly in the elderly and/or frail patient. Thus, the adage 'start low, go slow' will generally apply to the use of any drug, and particularly those with CNS effects.

In addition to the impact of ESKD and familiarity, the selection of the most appropriate symptom relief drug in ESKD also requires the prescriber to consider any relevant additional factors such as the presence of concurrent symptoms, co-morbidities (e.g. cardiovascular disease, liver impairment), other drugs (e.g. in relation to risk of a drug–drug interaction, QT prolongation) and patient preference.

### Drug dosing in dialysis

For patients on dialysis, the tables provide information on whether the effect of dialysis is sufficient to require a change in the dosing regimen of the drug. Unless specified otherwise, the information is relevant for both peritoneal dialysis (PD; continuous ambulatory or automated) and thrice weekly conventional haemodialysis (HD). However, because information is often limited and HD regimens are variable, some renal units adjust drug regimens for HD patients so that administration is timed to occur after the dialysis procedure.

Specialist advice should be sought for those patients on more frequent conventional HD, high flux dialysis or haemodiafiltration; drug removal is more likely and closer monitoring is required.<sup>10</sup>

## Antidepressants (Table 1)

Low starting doses and cautious titration are required for all antidepressants, regardless of whether they ( $\pm$  any active metabolites) are renally excreted. In ESKD there is an increased sensitivity to drugs acting on the CNS coupled with a risk of enhanced central depressant effects from the variable pharmacokinetic changes (Box A), e.g.:

- all the featured antidepressants (apart from venlafaxine) are highly protein bound
- all the featured antidepressants are dependent on one or more of CYP3A4, CYP2D6, CYP2C19 and CYP1A2
- metabolism will be further impaired in constitutionally poor metabolizers, e.g. amitriptyline, nortriptyline (CYP2D6), amitriptyline, citalopram and sertraline (CYP2C19), and the risk of toxicity increased from a pharmacokinetic drug-drug interaction involving an inhibitor of the CYP450 enzyme(s).

Concurrent use of other drugs with CNS depressant activity, e.g. opioids, increases the risk of toxicity.

Because of the time taken to accumulate, undesirable effects may become apparent only after days or weeks of regular use for those antidepressants with long half-lives, e.g. amitriptyline, citalopram, mirtazapine, nortriptyline and sertraline.

## Choice of antidepressant

From a renal perspective, the first-line antidepressant of choice for the treatment of depression in ESKD is sertraline. Citalopram can be used cautiously, but has a risk of prolongation of the QT interval (and increased risk of ventricular arrhythmia), e.g. as a result of possible accumulation, electrolyte imbalance, drug-drug interaction or concurrent use of other QT prolonging drugs.

If an SSRI is not suitable, some renal units favour the cautious use of mirtazapine for depression, despite it being extensively excreted unchanged by the kidney and known to accumulate in ESKD.

Amitriptyline and nortriptyline may be used with caution for neuropathic pain, but starting doses in ESKD should be low. The presence of cardiac co-morbidity may limit their use.

For patients on PD or HD, none of the drugs in Table 1 require any additional changes to the ESKD dosing regimen.

Table 1  
Antidepressants and ESKD. Before use, see introductory and class specific text

Antidepressant <sup>a</sup>	Half-life in normal renal function (h)	Active metabolite(s) <sup>b</sup>	Accumulation in renal impairment <sup>c</sup>	Removed by dialysis <sup>d</sup>	Dose and comment
Generally safe Sertraline <sup>e</sup>	26	No	No	No	Dose unchanged PO: start with 25mg each morning
Use cautiously Amitriptyline <sup>e</sup>	9e25	Yes	Possible	No	Lower doses may be sufficient PO: start with 10mg at night Not a first-line treatment for depression
Citalopram <sup>e</sup>	36	Yes	Possible	No	Dose unchanged; lower doses may be PO: start with 10mg each morning;
Nortriptyline <sup>e</sup>	15e39	Yes	Possible	No	Lower doses may be sufficient PO: start with 10mg at night Not a first-line treatment for depression
Trazodone	5e13	Yes	Possible	No	Lower doses may be sufficient PO: start with 25e50mg at night Not a first-line treatment for depression
Avoid if possible Duloxetine	8e17	No	Yes	No	If unavoidable, use lower doses PO: start with 30mg at night
Mirtazapine <sup>e</sup>	20e40	Yes	Yes	No	If unavoidable PO: start with 15mg at night
Venlafaxine	5 (11 <sup>f</sup> )	Yes	Yes	No	If unavoidable PO: start with 37.5mg daily, maximum 24h in divided doses For HD patients PO: dose after HD session to minimise undesirable effects

<sup>a</sup>whichever antidepressant is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than usual titration and close monitoring of the patient is required

<sup>b</sup>of actual or potential clinical relevance in ESKD

<sup>c</sup>of drug and/or active metabolite(s); 'possible' has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds

<sup>d</sup>sufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice

<sup>e</sup>because of a long half-life and time taken to reach steady state, undesirable effects with these antidepressants may only become apparent after several days or weeks of regular use

<sup>f</sup>active metabolite.

## Anti-emetics (Table 2)

In addition to any specific advice because of reduced elimination, for any individual anti-emetic, lower starting doses should be used, and then cautiously titrated to response. This is because patients are at risk of an enhanced central depressant effect as a result of reduced hepatic clearance (reduced CYP450 activity), reduced protein binding (increased unbound (active) fraction), and increased CNS levels and sensitivity (Box A). All of the featured anti-emetics are affected by one or more of these general consequences of renal impairment, albeit variably, e.g. domperidone does not cross the blood-brain barrier.

The risk of toxicity is also greater from a pharmacokinetic drug<sub>e</sub>drug interaction involving an inhibitor of the CYP450 enzyme. For example, CYP3A4 inhibitors will lead to reduced metabolism of domperidone.

The risk of prolongation of the QT interval (and the consequential increased risk of ventricular arrhythmia) is higher with domperidone, haloperidol, levomepromazine (methotrimeprazine) and ondansetron. The risk may be increased as a result of, e.g. drug accumulation, drug<sub>e</sub>drug interaction, concurrent use of other drugs that either prolong the QT interval or cause electrolyte imbalance.

Because of the time taken to accumulate, undesirable effects may become apparent only after days or weeks of regular use, for those anti-emetics with a long half-life, e.g. cyclizine, haloperidol and levomepromazine. Concurrent use of other drugs with CNS depressant activity, e.g. opioids, increases the risk of toxicity of anti-emetics with central effects.

## Choice of anti-emetic

Generally, all the anti-emetics used commonly in palliative care can be used in ESKD. Even those listed as 'use cautiously' are regularly used, in reduced doses, on renal units. Thus, choice should be primarily guided by the likely cause of the nausea and vomiting along with co-morbid conditions.

For patients on PD or HD, none of the drugs in Table 2 require any additional changes to the ESKD dosing regimen.

Table 2  
Anti-emetics and ESKD. Before use, see introductory and class specific text

Anti-emetics <sup>a</sup>	Half-life in normal renal function (h)	Active metabolite(s) <sup>b</sup>	Accumulation in renal impairment <sup>c</sup>	Removed by dialysis <sup>d</sup>	Dose and comment
Generally safe					
Cyclizine <sup>e</sup>	20	No	No	No	Dose unchanged; lower doses may be
Granisetron	4 <sup>e</sup> 11	No	No	No	Dose unchanged
Ondansetron	3 <sup>e</sup> 6	No	No	No	Dose unchanged
Prochlorperazine <sup>e</sup>	6 <sup>e</sup> 20	No	No	No	Lower doses may be sufficient
Use cautiously					
Domperidone <sup>f</sup>	7 <sup>e</sup> 9	No	Possible	No	PO: maximum 10mg daily <sup>e</sup> b.d.
Haloperidol	12 <sup>e</sup> 38	Yes	Possible	No	For occasional use, dose unchanged For regular use, halve the usual dose Also see Antipsychotics Table
Levomepromazine <sup>e</sup>	15 <sup>e</sup> 30	Yes	Possible	No	PO/SC: start with 6 <sup>e</sup> 6.25mg at night and p.r.n. up to q8h; lower doses may be sufficient, e.g. 2.5mg <sup>e</sup> 3mg
Metoclopramide <sup>f</sup>	4 <sup>e</sup> 6	No	Yes	No	PO/SC: start with 5mg t.d.s., maximum 10mg
Promethazine hydrochloride	5 <sup>e</sup> 14	No	No	No	PO: start with 10mg b.d., maximum 25mg t.d.s.

<sup>a</sup>whichever anti-emetic is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than usual titration and close monitoring of the patient is required

<sup>b</sup>of actual or potential clinical relevance in ESKD

<sup>c</sup>of drug and/or active metabolite(s); 'possible' has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds

<sup>d</sup>sufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice

<sup>e</sup>because of a long half-life and time taken to reach steady state, undesirable effects with these anti-emetics may only become apparent after several days or weeks of regular use

<sup>f</sup>domperidone and metoclopramide should be used at the lowest effective dose for the shortest possible time because of concerns over prolonged QT interval or drug-induced movement disorders respectively.

### Anti-epileptics (Table 3)

In addition to any specific advice because of reduced elimination, for any anti-epileptic, lower starting doses should be used, and then cautiously titrated to response. This is because patients are at risk of an enhanced central depressant effect as a result of reduced hepatic clearance (reduced CYP450 activity), reduced protein-binding (increased unbound (active) fraction) and increased CNS levels and sensitivity (Box A). All the featured anti-epileptics are affected by one or more of these general consequences of renal impairment, albeit variably, e.g.:

- reduced protein-binding affects the most highly protein-bound, e.g. phenytoin and valproate (for monitoring purposes, or when toxicity is suspected, the free fraction plasma concentration should be measured)
- all but levetiracetam, oxcarbazepine and gabapentin/pregabalin are dependent on CYP450
- the risk of toxicity is also greater from a pharmacokinetic drug—drug interaction involving an inhibitor of CYP450 or other enzymes responsible for metabolism of the anti-epileptic. For example:
  - > CYP3A4 inhibitors will lead to reduced metabolism of carbamazepine; CYP2C9 inhibitors, of phenobarbital and phenytoin; and CYP2C19 inhibitors, of phenytoin
  - > valproate, by inhibiting epoxide hydrolase may reduce the metabolism of carbamazepine.

Concurrent use of other drugs with CNS depressant activity, e.g. opioids, increases the risk of toxicity.

Because of the time taken to accumulate, undesirable effects may become apparent only after days or weeks of regular use for those anti-epileptics with a long half-life, e.g. carbamazepine, clonazepam, phenobarbital and phenytoin.

### Choice of anti-epileptic

From a renal perspective, the first-line anti-epileptic of choice in ESKD is valproate. Although carbamazepine is also 'renally clean', it is disadvantaged by drug—drug interactions. There does not appear to be any good evidence to support the commonly quoted advice to avoid modified-release formulations of anti-epileptics in ESKD.

Levetiracetam is increasingly used and the availability of a parenteral formulation is an advantage. It is primarily renally excreted, and thus accumulates in renal impairment. However, in reduced doses, it is authorized for use in ESKD ( $\pm$  dialysis), as are gabapentin and pregabalin. Gabapentin is used for pruritus and restless legs syndrome associated with ESKD,<sup>34</sup> and this may make its use for neuropathic pain a sensible multiple-purpose option.

There is an increased risk of toxicity from phenytoin; further, it is disadvantaged by drug—drug interactions. If it cannot be avoided, monitor plasma levels corrected for hypo-albuminaemia using the formula modified for ESKD.<sup>35</sup>

Phenobarbital is not generally used except in conjunction with specialist neurological advice.

For patients on PD or HD, specific changes to the dosing regimens are required for gabapentin, levetiracetam and pregabalin. The clinical effect should be monitored carefully for valproate, as the effect of dialysis may be variable.

Table 3  
Anti-epileptics and ESKD. Before use, see introductory and class specific text

Antiepileptic <sup>a</sup>	Half-life in normal renal function (h)	Active metabolite(s) <sup>b</sup>	Accumulation in renal impairment <sup>c</sup>	Removed by dialysis <sup>d</sup>	Dose and comment
Generally safe					
Carbamazepine <sup>e</sup>	16-36	No	No	No	Dose unchanged
Valproate	6-20	No	Possible	No	Dose unchanged; lower doses may be sufficient
Use cautiously					
Clonazepam <sup>e</sup>	20-60	Yes	Possible	No	Lower doses may be sufficient PO: start with 500microgram/24h Also see Benzodiazepines Table For non-dialysis or PD patients PO: start with 100mg on alternate nights and titrate slowly
Gabapentin	5-7	No	Yes	Yes	For HD patients with a urine output >100mL/24h PO: start with 100mg at night; consider either a supplementary dose after each HD session or timing the daily dose post HD For anuric HD patients PO: start with 100mg stat and 100mg after every HD session; a regular maintenance dose is generally not required
Levetiracetam	6-8	No	Yes	Yes	For non-dialysis patients PO/IV: start with 250mg b.d., maximum dose 500mg b.d. If <50kg, dose on a mg/kg basis (see SPC) For PD or HD patients PO/IV: start with 750mg stat and give the maintenance dose (above) as a once daily dose, consider either a supplementary dose of 250-500mg after each HD session or timing the daily dose post HD
Oxcarbazepine	1-3 (9 <sup>f</sup> )	Yes	Yes	Unknown	PO: maximum starting dose 150mg b.d., lower doses may be sufficient, e.g. 75mg b.d., titrate by 75mg at weekly intervals
Pregabalin	5-9	No	Yes	Yes	For non-dialysis or PD patients PO: start with 25mg once daily, maximum dose 75mg once daily For HD patients PO: consider either a supplementary dose of 25-100mg after each HD session or timing the daily dose post HD
Avoid if possible					
Phenytoin <sup>d</sup>	20-60	No	An increase in the free (unbound fraction) can occur to a clinically significant degree; high risk of toxicity due to the narrow therapeutic range	Phenobarbital <sup>d</sup>	75-120 No Possible No If unavoidable, use only under specialist neurological advice No If unavoidable, dose as in normal renal function. Monitor plasma levels adjusted for hypo-albuminaemia in ESKD, see text

<sup>a</sup>whichever antiepileptic is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than usual titration and close monitoring of the patient is required

<sup>b</sup>of actual or potential clinical relevance in ESKD

<sup>c</sup>of drug and/or active metabolite(s); 'possible' has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds

<sup>d</sup>sufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice

<sup>e</sup>because of a long half-life and time taken to reach steady state, undesirable effects with these anti-epileptics may only become apparent after several days or weeks of regular use

<sup>f</sup>active metabolite.



## Antipsychotics (Table 4)

In addition to any specific advice because of reduced elimination, for any individual antipsychotic, lower starting doses should be used, and then cautiously titrated to response. This is because patients are at risk of an enhanced central depressant effect as a result of reduced hepatic clearance (reduced CYP450 activity), reduced protein-binding (increased unbound (active) fraction) and increased CNS levels and sensitivity (Box A). All of the featured antipsychotics are affected by one or more of these general consequences of renal impairment, albeit variably, e.g.:

- all the featured antipsychotics are highly protein bound
- all the featured antipsychotics are dependent on one or more of CYP3A4, CYP2D6, and CYP1A2; the risk of toxicity is greater from a pharmacokinetic drug-drug interaction with inhibitors of the relevant CYP450, e.g. haloperidol, quetiapine, risperidone (CYP3A4), haloperidol and risperidone (CYP2D6), and olanzapine (CYP1A2).

Undesirable effects may become apparent only after days or weeks of regular use for those antipsychotics with long half-lives, e.g. haloperidol, olanzapine, risperidone. Concurrent use of other drugs with CNS depressant activity, e.g. opioids, increases the risk of toxicity.

The risk of prolongation of the QT interval (and increased risk of ventricular arrhythmia) may be higher with haloperidol and lowest for quetiapine. The risk may be increased as a result of, e.g. drug accumulation, drug–drug interaction, concurrent use of other drugs that either prolong the QT interval or cause electrolyte imbalance.

## Choice of antipsychotic

From a renal perspective, olanzapine is a good first-line choice in ESKD; it is also least dependent on CYP450 for its metabolism. Haloperidol can also be used cautiously, halving the dose for chronic use. For the use of levomepromazine as an anti-emetic, see Table 2.

For patients on PD or HD, haloperidol, olanzapine and quetiapine do not require any additional changes to the ESKD dosing regimen. Risperidone should be avoided due to unpredictable drug removal.

Table 4  
Antipsychotics and ESKD. Before use, see introductory and class specific text

Antipsychotic <sup>a</sup>	Half-life in normal renal function (h)	Active metabolite(s) <sup>b</sup>	Accumulation in renal impairment <sup>c</sup>	Removed by dialysis <sup>d</sup>	Dose and comment
Generally safe Olanzapine <sup>e</sup>	34 (52 elderly)	No	No	No	Lower doses may be sufficient PO: maximum starting dose 5mg/24h
Use cautiously Haloperidol <sup>e</sup>	12–8	Yes	Possible	No	For occasional use, dose unchanged. For regular use, halve the usual dose Also see Anti-emetics Table
Quetiapine	6–14	Yes	Possible	No	Lower doses may be sufficient PO: maximum starting dose 25mg/24h
Avoid if possible Risperidone <sup>e</sup>	20 <sup>f</sup>	Yes	Yes	Yes	If unavoidable, use lower doses PO: start with 500microgram b.d. and titrate in steps of 500microgram b.d. every 3–4 days For PD or HD patients Avoid due to unpredictable drug removal

<sup>a</sup>whichever antipsychotic is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than usual titration and close monitoring of the patient is required

<sup>b</sup>of actual or potential clinical relevance in ESKD

<sup>c</sup>of drug and/or active metabolite(s); 'possible' has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds

<sup>d</sup>sufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice

<sup>e</sup>because of a long half-life and time taken to reach steady state, undesirable effects with these antipsychotics may only become apparent after several days or weeks of regular use

<sup>f</sup>total for the parent drug and active metabolite.

## Benzodiazepines (Table 5)

In addition to any specific advice because of reduced elimination, for any individual benzodiazepine, lower starting doses should be used, and then cautiously titrated to response. This is because patients are at risk of an enhanced central depressant effect as a result of reduced hepatic clearance (reduced CYP450 activity), reduced protein-binding (increased unbound (active) fraction) and increased CNS levels and sensitivity (Box A). All of the featured benzodiazepines are affected by one or more of these general consequences of renal impairment, albeit variably, e.g. lorazepam elimination is not dependent on CYP450.

The risk of toxicity is also greater from a pharmacokinetic drug-drug interaction involving an inhibitor of the CYP450 enzyme mostly responsible for metabolism of the benzodiazepine, e.g. clonazepam and diazepam (CYP3A4), and diazepam (CYP2C19).

All the featured benzodiazepines have a long half-life and thus take time to accumulate. Undesirable effects may become apparent only after days or weeks of regular use. Concurrent use of other drugs with CNS depressant activity, e.g. opioids, increases the risk of toxicity.

## Choice of benzodiazepine

From a renal point of view, lorazepam is a good first-line choice. Clonazepam can also be used cautiously and is used by some renal units for restless legs syndrome associated with ESKD. Diazepam should be avoided if possible due to the risks of accumulation from an active metabolite with a very long half-life. Even so, some patients with ESKD tolerate it.

For patients on PD or HD, none of the drugs in Table 5 require any additional changes to the ESKD dosing regimen.

Table 5  
Benzodiazepines and ESKD. Before use, see introductory and class specific text

Benzodiazepine <sup>a</sup>	Half-life in normal renal function (h)	Active metabolite(s) <sup>b</sup>	Accumulation in renal impairment <sup>c</sup>	Removed by dialysis <sup>d</sup>	Dose and comment
Generally safe Lorazepam <sup>e</sup>	10-20	No	No	No	Lower doses may be sufficient SL/PO: start with
Use cautiously Clonazepam <sup>e</sup>	20-60	Yes	Possible	No	Lower doses may be sufficient PO: start with 500microgram/24h Also see Anti-epileptics Table
Avoid if possible Diazepam <sup>e</sup>	25-50 (#200 <sup>f</sup> )	Yes	Yes	No	If unavoidable, use half the usual

<sup>a</sup>whichever benzodiazepine is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than usual titration and close monitoring of the patient is required

<sup>b</sup>of actual or potential clinical relevance in ESKD

<sup>c</sup>of drug and/or active metabolite(s); 'possible' has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds

<sup>d</sup>sufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice

<sup>e</sup>because of a long half-life and time taken to reach steady state, undesirable effects with these benzodiazepines may only become apparent after several days or weeks of regular use

<sup>f</sup>active metabolite.

Table 6  
Miscellaneous drugs and ESKD. Before use, see introductory and class specific text

Drug <sup>a</sup>	Half-life in normal renal function (h)	Active metabolite(s) <sup>b</sup>	Accumulation in renal impairment <sup>c</sup>	Removed by dialysis <sup>d</sup>	Relative safety	Dose and comments
Antidiarrhoeals						
Loperamide	9e14	No	No	No	Use cautiously	Dose unchanged; lower doses may be sufficient
Antimuscarinics						
Glycopyrronium	1e1.5	Yes	Yes	Unknown	Use cautiously	SC: Start with 200microgram p.r.n.; lower doses may be PO: dose unchanged
Hyoscine butylbromide	5e10	No	No	No	Generally safe	CSCI or PO: dose unchanged
Bisphosphonates and denosumab						
Denosumab	624	No	No	No	Generally safe	Dose unchanged; see text
Ibandronic acid	10e72	No	Yes	No	Use cautiously	For prevention of skeletal-related events in patients with bone metastases in breast cancer: PO: 50mg once weekly IVI : 2mg in 500mL 0.9% saline or 5% glucose over 1h every 3e4 weeks For tumour-induced hypercalcaemia, seek specialist renal unit advice
Pamidronate disodium	1e27	No	Yes	No	Avoid if possible	For tumour-induced hypercalcaemia, seek specialist renal unit advice
Zoledronic acid	146	No	Yes	No	Avoid if possible	See text
Corticosteroids					Generally safe	See text
Laxatives					Generally safe	See text
Non-opioids						
Paracetamol	1e4	Yes	Possible	No	Use cautiously	PO: start with 500mg q6e8h; maximum 3g/24h IV: see SPC; minimum interval 6h
Nefopam	4 (10e15) <sup>e</sup>	Yes	Possible	No	Use cautiously	PO: maximum 30mg t.d.s.
NSAIDS				No	Avoid if possible	See text
Skeletal muscle relaxants						
Baclofen	3e4	No	Yes	Yes	Avoid if possible	If unavoidable PO: maximum 5mg once daily For HD patients Dose after HD session
Tizanidine	3	No	Yes	No	Use cautiously	PO: start with 2mg once daily; if necessary, slowly titrate in 2mg steps. Only increase the frequency of administration if a single daily dose is inadequate

<sup>a</sup>whichever drug is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than usual titration and close monitoring of the patient is required

<sup>b</sup>of actual or potential clinical relevance in ESKD

<sup>c</sup>of drug and/or active metabolite(s); 'possible' has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds

<sup>d</sup>sufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice

<sup>e</sup>for active metabolite.

---

## Miscellaneous drugs (Table 6)

The relative safety and dose adjustments for other common palliative care drugs in ESKD are shown in Table 6.

Full data have not been included for corticosteroids or laxatives. Corticosteroids, e.g. dexamethasone, fludrocortisone, hydrocortisone, methylprednisolone, prednisolone, can be used in normal doses. Similarly, commonly used laxatives, e.g. bisacodyl, docusate, lactulose, macrogols (polyethylene glycols), senna, are also generally safe in ESKD with doses unchanged. However, because of the amount of water required for their administration, macrogols should be used with caution and bulking agents, e.g. ispaghula (psyllium) husk, avoided completely.

Loperamide is highly protein bound, extensively metabolised by CYP3A4 and is a substrate for p-glycoprotein. In ESKD, lower doses may be sufficient, particularly in the presence of CYP3A4 and p-glycoprotein inhibitors, the latter potentially increasing the amount of loperamide within the CNS and the risk of central opioid effects.

Hyoscine butylbromide is generally safe in ESKD, and glycopyrronium can be used cautiously. However, for both, there is potential for greater CNS penetration due to the changes to the blood brain barrier.

Of the bisphosphonates, pamidronate disodium and zoledronic acid are both nephrotoxic, whereas the risk of renal toxicity with ibandronic acid is no greater than placebo.<sup>36</sup> Thus, for the reduction of skeletal-related events in cancer, the risk-benefit balance favours the use of ibandronic acid over other bisphosphonates. An alternative in this setting is denosumab, which is authorized for use in renal impairment and does not require dose adjustment.

The management of tumour-induced hypercalcaemia can be complex in ESKD, because of the need for caution with fluid administration and presence of other potentially contributing factors, e.g. tertiary hyperparathyroidism, use of vitamin D analogues, calcium-based phosphate binders. Thus, specialist renal unit advice should be sought.

For non-opioid analgesics, a reduced dose of paracetamol (acetaminophen) or nefopam is preferable to NSAIDs which should be avoided due to their nephrotoxicity. However, in anuric patients on dialysis, NSAIDs can be used in normal doses.

The choice of skeletal muscle relaxant in ESKD is not straightforward; for all, changes in the integrity of the blood brain barrier may result in increased penetration into the CNS. Baclofen and diazepam (also see Table 5) are best avoided because of the risks of accumulation. Even so, many renal units report that patients can tolerate low doses of diazepam. However, the better long-term option may be the cautious use of tizanidine in reduced doses. CYP1A2 inhibitors can significantly reduce the metabolism of tizanidine, and the concurrent use of ciprofloxacin and fluvoxamine is contra-indicated.

For patients on PD or HD, apart from baclofen for which dosing is recommended after HD, none of the featured drugs requires any additional changes to the ESKD dosing regimen.

## References

1. Douglas C, Murtagh FE, Chambers EJ, Howse M, Ellershaw J. Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. *Palliat Med* 2009;23:103-110.
2. Dean M. Opioids in renal failure and dialysis patients. *J Pain Symptom Manage* 2004;28:497-504.
3. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. *J Pain Palliat Care Pharmacother* 2007;21: 5-16.
4. King S, Ferro C, Chambers E, Forbes K, Hanks GA. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European palliative care research collaborative opioid guidelines project. *Palliat Med* 2011;25:525-552.
5. UK Medicines Information. What factors need to be considered when dosing patients with renal impairment? *Medicines Q&A*. 2016;167.6.
6. Twycross R, Wilcock A, Howard P. The Palliative Care Formulary, 5th ed. Nottingham: [Palliativedrugs.com](http://Palliativedrugs.com) Ltd., 2014. Available from [www.palliativedrugs.com](http://www.palliativedrugs.com). Accessed March 2, 2017.
7. McEvoy GK. American Hospital Formulary Service, Maryland, USA: American Society of Health-System Pharmacists. Available from [www.medicinescomplete.com](http://www.medicinescomplete.com). Accessed April 3, 2017.
8. Sweetman SC. Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Available from [www.medicinescomplete.com](http://www.medicinescomplete.com). Accessed March 2017.

9. Brown EA, Murtagh EM, Murphy E. Kidney disease from advanced disease to bereavement, 2nd ed. Oxford: Oxford University Press, 2012.

10. Ashley C, Dunleavy A. The Renal Drug Database, Oxford, UK: CRC Press. Available from <http://renaldrugdatabase.com>. Accessed May 2017.
11. Dawling S, Lynn K, Rosser R, Braithwaite R. Nortriptyline metabolism in chronic renal failure: metabolite elimination. *Clin Pharmacol Ther* 1982;32:322-329.
12. Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). *Nephrol Dial Transplant* 2012;27:3736-3745.
13. Taylor D, Paton C, Kapur S. Use of psychotropics in special patient groups: Renal Impairment. In: The Maudsley Prescribing Guidelines, 11th ed. The South London and Maudsley NHS Foundation Trust, UK: Wiley-Blackwell, 2012.
14. UK Medicines Information. What is the first choice antidepressant for patients with renal impairment? *Medicines Q&A*. 2014;369.2.
15. Bayer AJ, Pathy MS, Ankier SI. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly. *Br J Clin Pharmacol* 1983;16:371-376.
16. Nilsen OG, Dale O, Husebo B. Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. *Pharmacol Toxicol* 1993;72:286-289.
17. Dahl SG, Bratlid T, Lingjaerde O. Plasma and erythrocyte levels of methotrimeprazine and two of its nonpolar metabolites in psychiatric patients. *Ther Drug Monit* 1982;4: 81-87.
18. Finn A, Collins J, Voyksner R, Lindley C. Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route. *J Clin Pharmacol* 2005;45: 1383-1390.
19. Vulliemoz S, Iwanowski P, Landis T, Jallon P. Levetiracetam accumulation in renal failure causing myoclonic encephalopathy with triphasic waves. *Seizure* 2009;18:376-378.
20. Tsanaclis LM, Allen J, Perucca E, Routledge PA, Richens A. Effect of valproate on free plasma phenytoin concentrations. *Br J Clin Pharmacol* 1984;18:17-20.
21. Sakkas GK, Giannaki CD, Karatzaferi C, Maridaki M, Koutedakis Y, Hadjigeorgiou GM, et al. Current trends in the management of uremic restless legs syndrome: a systematic review on aspects related to quality of life, cardiovascular mortality and survival. *Sleep Med Rev* 2015;21:39-49.
22. Asconape JJ. Use of antiepileptic drugs in hepatic and renal disease. *Handb Clin Neurol* 2014;119:417-432.
23. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis

patients: a randomized, placebo-controlled, double-blind trial. *Nephrol Dial Transplant* 2004;19:3137-3139.

24. Kangas L, Kanto J, Forsstrom J, Iisalo E. The protein binding of diazepam and N-demethyl-diazepam in patients with poor renal function. *Clin Nephrol* 1976;5:114-118.

25. Morrison G, Chiang ST, Koepke HH, Walker BR. Effect of renal impairment and hemodialysis on lorazepam kinetics. *Clin Pharmacol Ther* 1984;35:646-652.

26. Verbeeck R, Tjandramaga TB, Verberckmoes R, De Schepper PJ. Biotransformation and excretion of lorazepam in patients with chronic renal failure. *Br J Clin Pharmacol* 1976;3:1033-1039.

27. Cervelli MJ. *The renal drug reference guide*, 1st ed. Adelaide, South Australia: Kidney Health, 2007.

28. Mimoz O, Chauvet S, Gregoire N, Marchand S, Le Guern ME, Saleh A, et al. Nefopam pharmacokinetics in patients with end-stage renal disease. *Anesth Analg* 2010;111: 1146-1153.

29. Marie Curie Palliative Care Institute. Guidelines for the LCP drug prescribing in advanced chronic kidney disease. Liverpool Care Pathway for the dying patient. Liverpool, UK: National LCP Steering Group, 2008.

30. NHS Lothian. Symptom control in patients with chronic kidney disease/renal impairment. Palliative Care Guidelines 2011.

31. Royal Melbourne Hospital. Nephrology Symptom Management Guidelines. Australia. Available from [www.thermh.org.au](http://www.thermh.org.au). Accessed July 6, 2016.

32. Yorkshire Palliative Medicine Guidelines Group. Clinical guidelines for the use of palliative care drugs in renal failure 2006.

33. Micromedex Solution. Truven Health Analytics, Inc. Ann Arbor, USA. Available from [www.micromedexsolutions.com](http://www.micromedexsolutions.com). Accessed January 12, 2017.

34. Cheikh Hassan HI, Brennan F, Collett G, Josland EA, Brown MA. Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. *J Pain Symptom Manage* 2015;49:782-789.

35. Winter ME. *Basic Clinical Pharmacokinetics*, 5th ed. Philadelphia, USA: Lippincott Williams & Wilkins, 2009.

36. Geng CJ, Liang Q, Zhong JH, Zhu M, Meng FY, Wu N, et al. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials. *BMJ Open* 2015; 5:1-10.